Answers are grounded in this paper and cite their sources.
Until a few years ago, the most common cause of cobalamin deficiency in Western Europe and North America was pernicious anemia. Cobalamin deficiency resulting from malabsorption of the vitamin was considered to be quite uncommon, because the most common malady resulting in generalized intestinal malabsorption in these regions, celiac sprue, usually spares the ileum, the site where active absorption of the intrinsic factorcobalamin complex occurs. More recently it has been recognized that another common cause of cobalamin deficiency is an inability to assimilate cobalamin in food.1 Such a problem is seen mostly in the elderly, who, although able to absorb pure crystalline cobalamin in the form of cyanocobalamin when administered orally (as in a routine Schilling test), are unable to absorb cobalamin present in food.1-3 Cobalamin in food is bound to proteins, from which it must first be released in the free form. Only after its release from food does cobalamin bind initially to R protein in the lumen of the stomach and thereafter to gastric intrinsic factor in the lumen of the duodenum. A likely cause of the impaired release of cobalamin from food is the diminished availability of acid and pepsin, one or both of which are considered necessary for the release of cobalamin from its bound form. This is the likely mechanism for the poor absorption of cobalamin from food in patients with hypochlorhydria.4 The stomachs of such patients secrete very small amounts of acid and pepsin, not sufficient to release cobalamin from food. Yet, unlike those with pernicious anemia, patients with hypochlorhydria, such as from atrophic gastritis, do secrete sufficient amounts of intrinsic factor to enable them to absorb pure crystalline cyanocobalamin normally when given during a routine Schilling test. However, if the Schilling test is modified to test for the absorption of food cobalamin,1-4 such patients can be shown to have abnormally low absorption. The fact that acid and pepsin deficiency is responsible for the malabsorption of food cobalamin in many such subjects is proven, because the exogenous administration of acid and pepsin with food often corrects the defect.5 It is for similar reasons that some patients have poor absorption of cobalamin after partial gastrectomy4 or vagotomy.6 It is tempting to speculate, therefore, that the increased prevalence of cobalamin deficiency seen in the elderly due to the malabsorption of food cobalamin occurs because of the diminished secretion of acid and pepsin by the aging stomach. Indeed, the oxyntic mucosa does tend to become more atrophic with increasing age7 and acid secretion commensurately declines.8 The atrophic stomach also makes less intrinsic factor, because in the human both acid and intrinsic factor are secreted by the parietal cell. It is presumed, however, that the tiny amounts of intrinsic factor still released by the atrophic, aging stomach are sufficient to bring about normal absorption of cobalamin when tested in a routine Schilling test. Whereas such a hypothesis makes logical sense, no large studies have been carried out thus far to substantiate it. There are a few pieces of evidence in the literature that lead one to suspect that a relative hypochlorhydria may not be the sole cause in all elderly persons who appear to have problems with the assimilation of food cobalamin. For one thing, the malabsorption of food cobalamin is corrected in some but not all persons by exogenous acid and pepsin.5 In addition, there was an intriguing report where the malabsorption of food cobalamin in elderly subjects with achlorhydria was corrected by the oral administration of tetracycline.9 This would suggest that in some way bacterial overgrowth resulting from diminished acid in the stomach might be responsible for the poor assimilation of food cobalamin.9 A higher prevalence of Helicobacter pylori antibodies has also been reported in subjects with a severe impediment in the assimilation of food cobalamin.10 Whether the H. pylori gives rise to impaired food cobalamin assimilation by causing atrophic gastritis resulting in a severe degree of hypochlorhydria, or by some other mechanism, remains unknown at this time. Thus, there may be other reasons why some elderly persons are unable to assimilate cobalamin from food sources. Cobalamin deficiency in the elderly resulting from an inability to assimilate food cobalamin, like any other cause of cobalamin deficiency, frequently presents very insidiously. The patient is often not anemic, and may have a normal or only a slightly elevated mean corpuscular volume (MCV) and a normal or slightly low serum cobalamin level. If indeed the MCV and serum cobalamin levels are normal, how do we deem such a person cobalamin deficient? A person may be considered cobalamin deficient when serum levels of methyl malonic acid and/or homocysteine are abnormally high in the absence of any of the inherited disorders that can give rise to elevated levels of one or both of these substances. In mammals, cobalamin is known to have only two physiologic functions. It serves as a coenzyme for two very important reactions, the conversion of methyl malonyl coenzyme A to succinyl coenzyme A and of homocysteine to methionine. Therefore, whenever cobalamin is deficient for any reason, there is more of each substrate, methyl malonic acid (MMA) and homocysteine, present in the serum. It turns out that elevated levels of MMA or homocysteine are more sensitive indicators of cobalamin deficiency than serum cobalamin levels. Another, perhaps even earlier and more sensitive indicator of negative cobalamin balance is a low serum level of holo transcobalamin II.11 Assays of serum cobalamin measure cobalamin bound to two transport proteins, haptocorrin and transcobalamin II. Only around 20% of cobalamin in serum is bound to transcobalamin II, and this is the form in which cobalamin crosses cell membranes to enter cells where it is required for DNA synthesis and other biochemical functions alluded to earlier. Therefore, holotranscobalamin II is a more sensitive and earlier indicator of a negative cobalamin balance than is total serum cobalamin.11 Assays for serum MMA and homocysteine are now readily available to all clinicians, whereas the assay for holotranscobalamin II is as yet unavailable except in special research facilities. Is it really important to identify cobalamin deficiency before the patient develops its early manifestations, such as a slightly elevated MCV accompanied by a low serum cobalamin level? Until a few years ago it was believed that the neuropsychiatric manifestations of cobalamin deficiency only occurred late in its course. Indeed, if the spectrum of the neuropsychiatric manifestations of cobalamin deficiency were confined to the earlier, classic descriptions of symptomatic peripheral neuropathy, subacute combined degeneration of the spinal cord, and socalled megaloblastic madness, then that is frequently the case. However, symptoms such as depression, dementia, and sensory ataxia can occur in the presence of normal levels of serum cobalamin and in the absence of anemia or any of the typical features of cobalamin deficiency seen on a peripheral blood smear. In such cases the etiology of the patient's symptoms becomes evident only when elevated levels of serum MMA and/or homocysteine are identified.2,3 Furthermore, the administration of cobalamin at this stage can result in the reversal of symptoms.2 What is the age-specific prevalence of cobalamin deficiency in the general population, arising chiefly, though not exclusively, from the malassimilation of food cobalamin? As yet we have little accurate information. However, the results of a few carefully conducted studies in special populations suggest that the prevalence is not insignificant.12,13 Clearly what is required are extensive population studies that use more sensitive measurements such as serum levels of MMA, homocysteine, and holotranscobalamin II. We live in an era when medications that suppress acid secretion-H2-receptor antagonists and proton pump inhibitors-are some of the most commonly prescribed. In fact, H2-receptor antagonists are now available over the counter. In all honesty, one could not be considered to be judgmental of one's peers if one suggested that the use of these agents is frequently inappropriate. How does the prolonged use of these agents, in particular proton pump inhibitors, impact on cobalamin absorption, particularly in the elderly? A careful analysis of the data available thus far is presented in this issue of the Journal of Clinical Gastroenterology by Howden.14 According to this review of the current literature, in which determination of cobalamin deficiency is based on measurement of serum cobalamin levels, it would appear that there is little reason for concern. Very few, if any, of the patients taking proton pump inhibitors for a few years developed low serum cobalamin levels. Yet the use of both H2-receptor antagonists15 and proton pump inhibitors,16 even for a few weeks, significantly diminishes the absorption of "food" cobalamin when measured by a modified Schilling test. For persons with an intact enterohepatic circulation of cobalamin, it could take up to a decade or more to develop low levels of serum cobalamin. Would some of these patients taking long-term proton pump inhibitors eventually develop low serum levels of cobalamin? Patients on long-term proton pump inhibitors who have Zollinger-Ellison syndrome are not a suitable population to monitor for cobalamin deficiency. These patients, despite receiving very large doses of antisecretory drugs, seldom achieve a hypochlorhydric state. However, several patients are given life-long proton pump inhibitor prescriptions for treatment of gastroesophageal reflux disease or as prophylaxis against the ulcerogenic effects of nonsteroidal antiinflammatory drugs. Countless other patients, unfortunately, are prescribed these agents inappropriately for nonulcer dyspepsia or functional dyspepsia and, occasionally, even for irritable bowel syndrome! Even for patients who receive these agents long term, the risk of developing megaloblastic anemia is insignificant. However, no large studies have examined serum levels of MMA and homocysteine or measured holotranscobalamin II levels. As mentioned earlier, subtle but worrisome neuropsychiatric disorders occur quite frequently despite normal levels of serum cobalamin.2,3 Such patients could be identified by using the more sensitive assays, rather than merely depending on serum cobalamin levels. Therefore, at this time, one cannot categorically state that the prolonged use of proton pump inhibitors is totally without risk for the development of cobalamin deficiency, because the studies using tests more sensitive than measurement of serum cobalamin have not as yet been carried out. Does that mean that physicians should periodically screen patients receiving proton pump inhibitors or large doses of H2-receptor antagonists for prolonged periods, using costly serum assays for MMA and homocysteine? To do so until more cost-benefit studies are performed would be an misuse of resources. However, a level of clinical vigilance is called for. In the event such patients develop some of the subtle neurological or psychiatric symptoms recently described with occult cobalamin deficiency,2,3 a serum cobalamin level should be obtained. If this is normal, the clinician should not rest there, but should then order serum MMA and homocysteine levels. Yet this practice is no different from that advocated for all patients, whether they are on long-term acid suppression therapy or not. So in the end, a well-informed physician for now need do nothing special for his or her patient on long-term acid suppression therapy. It is time now to obtain some core information about the prevalence of cobalamin deficiency using tools more sensitive than measurement of serum cobalamin levels. Initially, large cross-sectional population studies need to be carried out. Simultaneously, it would be appropriate to perform longitudinal cohort studies, at least on special populations such as patients on long-term acid suppression therapy. Timely administration of cobalamin to patients with elevated MMA or homocysteine levels might prevent the development of serious neuropsychiatric symptoms or ameliorate already existing ones. There is another reason to acquire such information. There is much talk at this time of prescribing folic acid as a supplement to middle-aged and older persons at risk for developing atherosclerosis, with the object of avoiding homocysteinemia. Even if physicians do not prescribe folic acid, it is likely to be taken by large numbers of persons who believe in the virtues of megavitamin therapy. The administration of folic acid to patients with occult cobalamin deficiency has long been known to precipitate neurological crises. If a significant proportion of the middle-aged or elderly population has elevated levels of MMA or homocysteine or low levels of holotranscobalamin II, it might be worth considering providing persons receiving folic acid with cobalamin supplements as well. It is also about time that clinicians, especially those that see the elderly, entertain the possibility of cobalamin deficiency when they encounter patients who present with some of the subtle manifestations of this deficiency.2,3 In all such cases, although it is cost effective to begin by ordering a serum cobalamin measurement, if the serum level of the vitamin is in the normal range the clinician should go further and request serum MMA and homocysteine levels. It is surprising how infrequently this is done in routine clinical practice, not only by general internists but also by neurologists and psychiatrists. Cyrus Kapadia, M.D.
No takes yet. Share an insight, caveat, or question.
Cyrus R. Kapadia (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: